Brief: Clinical Evidence Supports Rapid SUBLOCADE Induction As A Strategy To Improve Retention In Opioid Use Disorder Treatment
15/10/2025 13:13
Oct 15 (Reuters) - Indivior PLC 2IVB.D: CLINICAL EVIDENCE SUPPORTS RAPID SUBLOCADE® INDUCTION AS A STRATEGY TO IMPROVE RETENTION IN OPIOID USE DISORDER TREATMENT INDIVIOR PLC - RAPID INDUCTION WITH SUBLOCADE WELL TOLERATED INDIVIOR PLC - SECOND SUBLOCADE INJECTION WELL TOLERATED AFTER ONE WEEK Source text: ID:nPn6fkT3Ba Further company coverage: 2IVB.D
Recent news on Indivior Pharmaceuticals
See all newsIndivior Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Supernus soars on Indivior merger, Q2 revenue beat
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates